Purpose: To prospectively characterize macular structure and function as assessed by combined three-dimensional spectral-domain optical coherence tomography and scanning laser ophthalmoscopy and 3D computer-automated threshold Amsler grid, respectively, in a patient undergoing pharmacologic vitreolysis for vitreomacular adhesion with tractional cysts.
Purpose: To prospectively characterize macular structure and function as assessed by combined three-dimensional spectral-domain optical coherence tomography and scanning laser ophthalmoscopy and 3D computer-automated threshold Amsler grid, respectively, in a patient undergoing pharmacologic vitreolysis for vitreomacular adhesion with tractional cysts.
Methods: Combined 3D optical coherence tomography and scanning laser ophthalmoscopy measured macular volume and 3D computer-automated threshold Amsler grid quantified central visual field function by determining the absolute percent magnitude lost (cumulative value of total visual field loss over all tested levels) before and for a period of 6 months after pharmacologic vitreolysis for vitreomacular adhesion with a single intravitreal injection of microplasmin (125 mg; ThromboGenics).
Results: Ocriplasmin pharmacologic vitreolysis released vitreomacular adhesion by 2 weeks and decreased macular volume from 0.32 mL to 0.15 mL by 1 year after injection. There was a concomitant 4-fold improvement in visual function as measured by 3D computer-automated threshold Amsler grid (percent of central visual field lost) and Snellen visual acuity improved from 20/200 to 20/40.
Conclusion: For assessing macular function improvement in conjunction with structural reintegration after pharmacologic vitreolysis for vitreomacular adhesion, 3D computerautomated threshold Amsler grid is a useful tool. Both 3D measurements quantitatively characterized the resolution of this patient's vitreomacular adhesion, suggesting that this is a useful approach to quantifying macular structure and function as indices of the severity of disease and the response to therapy. ). Three-dimensional CTAG has the added benefit of providing quantitative indices that can be used to follow changes in visual function over time. One valuable 3D-CTAG index is the absolute percent magnitude lost, which incorporates all five tested contrast levels to calculate the cumulative percent of visual field lost. This index is calculated by dividing the number of points tested where a defect was detected by the total number of points tested and describes the absolute size of the defect regardless of its shape. Using this index provides an objective and reproducible way to measure temporal changes in disease severity on a functional level and quantify the response to therapy.
RETINAL CASES & BRIEF REPORTS
Similarly, spectral-domain optical coherence tomography (OCT) combined with scanning laser ophthalmoscopy (SD-OCT/SLO) provides 3-D quantitative indices that can be followed prospectively, such as macular volume and thickness. Combining the superior resolution of SD-OCT with a confocal SLO allows for precise correlation of a quantitative measurement to a specific fundus location, thus making it more reliable to track changes in macular structure over time.
Vitreomacular adhesion (VMA) is presently treated surgically with pars planar vitrectomy and membrane peeling, often with chromodissection (Bababeygy and Sebag 7 ). Although effective, this surgical approach is not without inherent risks and costs. Recent developments in pharmacologic vitreolysis may obviate the need for surgery in the future (Sebag 8, 9 ). Initially, pharmacologic agents were tested as adjuncts to surgery, but recent work has explored the potential of pharmacologic vitreolysis as a stand-alone treatment for inducing a total posterior vitreous detachment without surgery. One agent that is currently under development is ocriplasmin, a 29-kDa recombinant truncated form of human plasmin (Stalmans et al 10 ) . In this report, we characterize the 3D structural and functional changes in a patient with VMA and cystic changes who successfully underwent pharmacologic vitreolysis with a single injection of ocriplasmin. The patient was followed prospectively for 15 months starting before treatment, with both 3D-CTAG and 3D SD-OCT/SLO. Reprint requests: Kevin R. Tozer, BS, 1355 San Pablo Street, DVRC 307, Los Angeles, CA 90033; e-mail: ktozer@usc.edu lost. The patient was enrolled in the MIVI-IIT (Micrplasmin for IntraVitreous Injection for treatment vitreomacular Traction) clinical trial and, following informed consent, was randomized to a single injection (125 mg in 100 mL) of microplasmin (Ocriplasmin; Thrombogenics, Leuven, Belgium). Table 1 shows the progression of all quantitative structural (3D-OCT/SLO) and functional (visual acuity and 3D-CTAG) indices over time.
Case Report
One week after injection, the patient had decreased metamorphopsia and best-corrected visual acuity of 20/40-2 in the treated eye. At 2 weeks after the injection, 3D-OCT/SLO imaging revealed resolution of VMA and vitreopapillary adhesion (Figure 3) . Macular volume had decreased to 0.22 mL (31.25% improvement from preinjection level), and nearly all cystoid spaces had resolved. Repeat 3D-CTAG evaluation revealed a smaller central conical defect (Figure 2 ) with a 0.66 absolute percent magnitude lost (nearly 4-fold improvement from preinjection level). At 1 month, the macular volume had only changed slightly to 0.21 mL while the absolute percent magnitude lost on 3D-CTAG actually increased slightly to 0.99. At 6 months after injection, the macular volume was still 0.21 mL, and 3D-CTAG measured an absolute percent magnitude lost of 0.65. At 15 months, macular volume improved to 0.15 mL.
Discussion
The past two decades have witnessed considerable improvement in technology to image macular structure; however, there has been little concurrent progress in assessing macular function. This case demonstrates the utility of 3D-CTAG in assessing macular dysfunction and its recovery after successful resolution of VMA with ocriplasmin pharmacologic vitreolysis. The functional assessment by 3D-CTAG mirrored the structural improvement, as demonstrated by combined 3D SD-OCT/SLO. Although visual acuity registered a similar improvement, this indexed only foveal function (4°central visual field), while 3D-CTAG quantified the central 25°macular function improvement. Both the 3D-CTAG and the volumetric measurements of combined SD-OCT/SLO showed that while major improvement occurred in the first 2 weeks after treatment, there were residual structural and functional deficits present 6 months after the injection ( Table 1 ). The relative percent improvement in central macular volume over the first 2 weeks was 31% (0.32-0.22 mL), while the 3D-CTAG percent magnitude lost improved nearly 4-fold (from 2.24 to 0.66). Similarly, at 6 months, the central macular volume had improved slightly more to 0.21 mL (34% overall improvement), and the absolute percent magnitude lost showed a similar small improvement to 0.65 (400% overall).
Previous studies (Nazemi et al, 2 Kim et al, 3 Nazemi et al, 4 Robison et al, 5 and Jivrajka et al 6 ) have shown that 3D-CTAG testing can differentiate various abnormalities based on specific patterns of visual dysfunction. For example, specific patterns were identified for wet versus dry AMD (Nazemi et al 4 This case demonstrates that 3D-CTAG correlates well with structural changes in the macula. Combining 3D-CTAG functional testing with advanced structural analysis should further our understanding of the role(s) that structural abnormalities play in affecting visual function of patients across a wide range of posterior segment abnormalities. Current studies (Tozer et al 12 ) are correlating structure and function in patients with macular pucker to quantify the level of statistical correlation between these two testing modalities. It is hoped that using 3D-CTAG to study the response to surgical and nonsurgical therapies will provide metrics for gauging the benefits of new therapies designed to restore visual function and not just structural integrity.
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